Literature DB >> 9600494

Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma.

M T Chan1, D Y Leung, S J Szefler, J D Spahn.   

Abstract

BACKGROUND: Although widely used, little is known regarding the patterns of response that subjects with severe asthma exhibit to oral glucocorticoid (GC) therapy.
METHODS: We retrospectively reviewed the charts of 164 consecutive adolescents admitted to the National Jewish Medical and Research Center for difficult-to-control asthma. Data collected included medical history, pulmonary function measures by plethysmography, methacholine challenge results, AM cortisol levels, serum IgE, total eosinophil counts (TEC), serum eosinophil cationic protein (ECP), soluble IL-2 receptor (sIL-2R), and spirometry.
RESULTS: Eighty-seven patients (53%) required a GC burst during the hospitalization secondary to poor asthma control. Those requiring a GC burst had a significantly longer history of asthma, a greater degree of bronchial hyperresponsiveness, and lower pulmonary function. Twenty-one patients (24%) failed to respond with a greater than 15% improvement in their AM prebronchodilator FEV1 after the GC burst and were termed steroid insensitive (SI). Although those with SI asthma had a similar duration of asthma, they required oral GC therapy at a younger age, required a larger maintenance oral GC dose on admission, and were more likely to be African-American, compared with those with steroid-sensitive asthma. Furthermore, two distinct spirometry patterns were noted among the SI asthmatic subjects: "chaotic" and "nonchaotic." Patients with the chaotic pattern were characterized by a significant degree of variability (greater than 30%) in daily pulmonary function, whereas those with nonchaotic, SI asthma were characterized by less than 15% variability in daily lung function. Those with nonchaotic SI were diagnosed with asthma and treated with oral GCs at a later age.
CONCLUSIONS: This retrospective study suggests that SI asthma is quite common (25%) among adolescents with severe asthma evaluated at a national referral center. In addition, two distinct patterns of SI asthma have been identified that may constitute different pathophysiologic processes. Finally, the overrepresentation of African-Americans in the SI group supports the need for further epidemiologic studies investigating the prevalence of SI asthma and the impact early asthma intervention may have on this severe form of asthma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600494     DOI: 10.1016/S0091-6749(98)70165-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  54 in total

1.  Airway inflammation in children with difficult asthma: relationships with airflow limitation and persistent symptoms.

Authors:  D N R Payne; Y Qiu; J Zhu; L Peachey; M Scallan; A Bush; P K Jeffery
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

Review 2.  Management of severe asthma in children.

Authors:  Andrew Bush; Sejal Saglani
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

3.  Nuclear bioavailability of the glucocorticoid receptor in a pediatric asthma cohort with variable corticosteroid responsiveness.

Authors:  Salomon Cornejo; Kelan Tantisira; Benjamin A Raby; Scott T Weiss; Feige Kaplan
Journal:  Pediatr Res       Date:  2015-08-13       Impact factor: 3.756

4.  Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients.

Authors:  Hakon Hakonarson; Unnur S Bjornsdottir; Eva Halapi; Jonathan Bradfield; Florian Zink; Magali Mouy; Hildur Helgadottir; Asta S Gudmundsdottir; Hjalti Andrason; Asdis E Adalsteinsdottir; Kristleifur Kristjansson; Illugi Birkisson; Thor Arnason; Margret Andresdottir; David Gislason; Thorarinn Gislason; Jeffrey R Gulcher; Kari Stefansson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

5.  Increasing adherence to inhaled steroid therapy among schoolchildren: randomized, controlled trial of school-based supervised asthma therapy.

Authors:  Lynn B Gerald; Leslie A McClure; Joan M Mangan; Kathy F Harrington; Linda Gibson; Sue Erwin; Jody Atchison; Roni Grad
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

6.  Methacholine PC20 in African Americans and whites with asthma with homozygous genotypes at ADRB2 codon 16.

Authors:  Kathryn Blake; James D Cury; Jobayer Hossain; Kelan Tantisira; Jianwei Wang; Edward Mougey; John Lima
Journal:  Pulm Pharmacol Ther       Date:  2013-02-04       Impact factor: 3.410

Review 7.  Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases.

Authors:  Joseph C Maranville; Anna Di Rienzo
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

8.  Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma.

Authors:  Wanda Phipatanakul; David T Mauger; Ronald L Sorkness; Jonathan M Gaffin; Fernando Holguin; Prescott G Woodruff; Ngoc P Ly; Leonard B Bacharier; Nirav R Bhakta; Wendy C Moore; Eugene R Bleecker; Annette T Hastie; Deborah A Meyers; Mario Castro; John V Fahy; Anne M Fitzpatrick; Benjamin M Gaston; Nizar N Jarjour; Bruce D Levy; Stephen P Peters; W Gerald Teague; Merritt Fajt; Sally E Wenzel; Serpil C Erzurum; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

9.  Targeting the phosphorylation site of myristoylated alanine-rich C kinase substrate alleviates symptoms in a murine model of steroid-resistant asthma.

Authors:  Chien-Neng Wang; Yu-Chao Lin; Bo-Chun Chang; Ching-Hsien Chen; Reen Wu; Chen-Chen Lee
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

10.  Trends in racial disparities for asthma outcomes among children 0 to 17 years, 2001-2010.

Authors:  Lara J Akinbami; Jeanne E Moorman; Alan E Simon; Kenneth C Schoendorf
Journal:  J Allergy Clin Immunol       Date:  2014-08-01       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.